Stay updated on Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2 and removed the prior operating-status notice (Revision: v3.4.1). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a site-wide notice about government funding affecting updates and the NIH Clinical Center's status. The page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedA new 'Show glossary' toggle is added, along with footer metadata showing 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0'. The deletions remove older wording/variants ('Last Update Submitted that met QC Criteria', 'No FEAR Act data', 'Revision: v3.3.4'), reflecting a minor UI update and data-label cleanup. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed; no study details, enrollment, or eligibility information appear to be changed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedA Locations section with a Washington entry has been added, improving visibility of where the study is conducted. The previous 'Washington Locations' entry and the HHS Vulnerability Disclosure have been removed.SummaryDifference0.2%

- Check92 days agoChange DetectedPublications description updated to indicate that items are automatically filled from PubMed and may not be about the study, and the Revision label changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.